Skip to main content
Premium Trial:

Request an Annual Quote

Genetika+ Snags CE Mark for Major Depressive Disorder Drug-Matching Test

NEW YORK – Genetika+ has obtained CE-IVD marking for its first drug-matching test focused on major depressive disorder (MDD), the precision medicine startup said Wednesday.

The Israeli company's product, a blood test dubbed NeuroKaire, is ordered by a physician. It predicts a patient's likelihood of responding to various antidepressants by combining patient-reported information about symptoms with pharmacogenetics testing and functional testing based on the patient's blood sample

The company's CE mark follows results from a multi-site study, in which NeuroKaire successfully predicted drug response for patients with MDD.

"This CE-IVD mark is an important milestone for Genetika+, demonstrating the accuracy and efficacy of this much needed tool in MDD and facilitating adoption of NeuroKaire in the European market," said Talia Cohen Solal, Genetika+'s CEO and cofounder, in a statement. The company is working with physicians and hospitals to deploy NeuroKaire in clinical care.

Genetika+ was founded in 2018 to improve personalized drug prescribing for psychiatric and neurological diseases. It received €17.5 million ($17.3 million) over the summer from the European Commission's European Innovation Council Accelerator to clinically validate and commercialize NeuroKaire. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.